Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury

• Published in: Journal of nephrology Vol. 34; no. 4; pp. 1263 - 1270
• Main Authors: Steiner, N., Abdel Hamid, A., Kronbichler, A., Neuwirt, H., Myslivecek, M., Kollar, M., Lachmanova, J., Rysava, R., Hruskova, Z., Spicka, I., Willenbacher, W., Nachbaur, D., Wolf, D., Tesar, V., Gunsilius, E.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.08.2021
• Subjects: Medicine; Medicine & Public Health; Nephrology; Original; Original Article; Urology; Cast nephropathy; Bortezomib; High-cut-off (HCO) hemodialysis; Acute kidney injury; Multiple myeloma
• ISSN: 1121-8428; 1724-6059
• DOI: 10.1007/s40620-020-00939-2

Background In patients with multiple myeloma (MM) free light chain-induced cast nephropathy is a serious complication associated with poor survival. High-cut-off (HCO) hemodialysis can reduce the amount of serum free light chains (sFLC), but data on its impact on clinical outcome is limited and contradictory. To gain further insights we collected real world data from two major myeloma and nephrology centers in Austria and the Czech Republic. Methods Sixty-one patients with MM and acute kidney injury, who were treated between 2011 and 2019 with HCO hemodialysis and bortezomib-based MM therapy, were analyzed. Results The median number of HCO hemodialysis sessions was 11 (range 1–42). Median glomerular filtration rate at diagnosis was 7 ± 4.2 ml/min/1.73m 2 . sFLC after the first HCO hemodialysis decreased by 66.5% and by 89.2% at day 18. At 3 and 6 months, 26 (42.6%) and 30 (49.2%) of patients became dialysis-independent. Conclusion The widely used strategy combining HCO hemodialysis and bortezomib-based antimyeloma treatment is dissatisfactory for half of the patients undergoing it and clearly in need of improvement.